Parfenova, Pourcyrous Awarded $2.5 Million to Study Neonatal Cerebral Vascular Disease Pathology - UTHSC News

[unable to retrieve full-text content]

Parfenova, Pourcyrous Awarded $2.5 Million to Study Neonatal Cerebral Vascular Disease Pathology  UTHSC News

Comments

Post a Comment

Popular posts from this blog

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease - Vascular Disease Management

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease    Vascular Disease Management First and only non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease; Follows ...
Read more